Skip to main content

Fiscal Wizard · Single-issue tearsheet

CELU / Jun 21, 2026 Run #7483

CELU

Celularity Inc.

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Composite verdict

F 8.8 / 100
Bearish setup · Trend Following 15 drivers · 5 gates blocking
  • Chaikin Money Flow
  • Coppock Curve
  • Vortex Signal
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 460th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 1Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

17.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Greenblatt EY 0
Asset Turnover 79
Return on Capital Employed 0
FCF Margin 75
Free Cash Flow Yield 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Chaikin Money Flow, Coppock Curve, Vortex Signal); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 12
Coppock Curve 12
Rate of Change 13

Risk Gates

5 blocking 6 caution

5 guards active, 18 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for CELU.